PMEL and melanoma: Ipilimumab at a dose of 3 mg/kg, given either alone or in combination with a glycoprotein 100 (gp100) peptide vaccine, significantly improved overall survival (OS) in patients with previously treated unresectable stage III or IV melanoma, compared with gp100 alone, and 1- and 2-year survival rates were reported as 45.6% vs. 25.3% and 23.5% vs. 13.7%, respectively[5].